Skip to content

DIFFUSION CHARACTERISTICS OF LETIBOTULINUMTOXIN A IN COMPARISON TO ONA AND ABO-BONTA

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511047-26-01
Acronym
20231129
Enrollment
30
Registered
2024-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable health without uncontrolled systemic diseases; Healthy skin testing area (forehead); Moderate to severe forehead wrinkling (in motion); Uniform sweating activity and no areas of anhidrosis (under standardized sweating conditions)

Brief summary

Maximum anhidrosis area; measured by the halo of anhidrosis

Detailed description

Range of anhidrosis at all other measured time points; Wrinkle Thickness (No Movement / Maximum Tension) measured by Live Evaluation and Evaluation via Standardized Photography; Area under the curve (anhidrosis area) within a period of 6 months; Patient satisfaction; Eyebrow position

Interventions

DRUGBOTOX 100 Allergan-Einheiten Pulver zur Herstellung einer Injektionslösung
DRUGDysport® 300 Einheiten Pulver zur Herstellung einer Injektionslösung

Sponsors

Hamburg University
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Maximum anhidrosis area; measured by the halo of anhidrosis

Secondary

MeasureTime frame
Range of anhidrosis at all other measured time points; Wrinkle Thickness (No Movement / Maximum Tension) measured by Live Evaluation and Evaluation via Standardized Photography; Area under the curve (anhidrosis area) within a period of 6 months; Patient satisfaction; Eyebrow position

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026